PL3157531T3 - Sposoby i kompozycje do stymulacji jelitowego układu enteroendokrynnego w leczeniu chorób lub stanów związanych z tym układem - Google Patents

Sposoby i kompozycje do stymulacji jelitowego układu enteroendokrynnego w leczeniu chorób lub stanów związanych z tym układem

Info

Publication number
PL3157531T3
PL3157531T3 PL15811714T PL15811714T PL3157531T3 PL 3157531 T3 PL3157531 T3 PL 3157531T3 PL 15811714 T PL15811714 T PL 15811714T PL 15811714 T PL15811714 T PL 15811714T PL 3157531 T3 PL3157531 T3 PL 3157531T3
Authority
PL
Poland
Prior art keywords
stimulation
compositions
methods
same
treating diseases
Prior art date
Application number
PL15811714T
Other languages
English (en)
Inventor
Michael Zasloff
Original Assignee
Enterin, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin, Inc. filed Critical Enterin, Inc.
Publication of PL3157531T3 publication Critical patent/PL3157531T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15811714T 2014-06-23 2015-06-22 Sposoby i kompozycje do stymulacji jelitowego układu enteroendokrynnego w leczeniu chorób lub stanów związanych z tym układem PL3157531T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462015657P 2014-06-23 2014-06-23
US14/329,627 US10040817B2 (en) 2013-10-03 2014-07-11 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
PCT/US2015/036935 WO2015200195A1 (en) 2014-06-23 2015-06-22 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
EP15811714.3A EP3157531B1 (en) 2014-06-23 2015-06-22 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Publications (1)

Publication Number Publication Date
PL3157531T3 true PL3157531T3 (pl) 2021-11-15

Family

ID=54869043

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15811714T PL3157531T3 (pl) 2014-06-23 2015-06-22 Sposoby i kompozycje do stymulacji jelitowego układu enteroendokrynnego w leczeniu chorób lub stanów związanych z tym układem

Country Status (18)

Country Link
US (10) US10040817B2 (pl)
EP (1) EP3157531B1 (pl)
JP (2) JP6692300B2 (pl)
CN (2) CN106535902B (pl)
BR (1) BR112016029917A2 (pl)
CA (1) CA2951720C (pl)
CY (1) CY1124554T1 (pl)
DK (1) DK3157531T3 (pl)
ES (1) ES2878077T3 (pl)
HR (1) HRP20211005T1 (pl)
HU (1) HUE054828T2 (pl)
LT (1) LT3157531T (pl)
MX (2) MX2016017368A (pl)
PL (1) PL3157531T3 (pl)
PT (1) PT3157531T (pl)
RS (1) RS62064B1 (pl)
SI (1) SI3157531T1 (pl)
WO (1) WO2015200195A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
US20180344748A1 (en) * 2017-05-31 2018-12-06 Enterin Laboratories, Inc. Methods and compositions for preventing or treating chronic inflammatory diseases
WO2019050903A1 (en) * 2017-09-08 2019-03-14 Enterin Laboratories, Inc. METHODS OF TREATING SLEEP DISORDERS, SLEEP DISTURBANCES AND ASSOCIATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS
MA50536A (fr) 2017-10-30 2020-09-09 Enterin Inc Nouvelles formes solides de squalamine et procédés pour les produire
US20190298740A1 (en) * 2018-03-27 2019-10-03 Enterin, Inc. Methods and compositions for treating hallucinations and conditions related to the same
AU2019285065A1 (en) * 2018-06-13 2021-01-07 Enterin, Inc. Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration
US20210315907A1 (en) * 2018-08-03 2021-10-14 Enterin, Inc, Compositions and methods for treating brain-gut disorders
WO2020028810A1 (en) * 2018-08-03 2020-02-06 Enterin Laboratories Compositions and methods for treating brain-gut disorders
EP3829537A4 (en) * 2018-08-03 2022-09-21 Enterin, Inc. LOW DOSAGE INTRANASAL DOSAGE FORMS OF AMINOSTEROL AND METHODS OF USE THEREOF
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
EP4007581A4 (en) * 2019-08-02 2023-10-25 Enterin, Inc. DOSAGE PROTOCOLS AND REGIMES FOR AMINOSTEROL TREATMENT

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
US5352682A (en) 1993-03-08 1994-10-04 Digestive Care Inc. Compositions containing salts of bile acid-aminosalicylate conjugates
WO1994020520A1 (en) 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
US5840740A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
AU3512595A (en) 1994-09-13 1996-03-29 Magainin Pharmaceuticals, Inc. Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds
US5834453A (en) 1995-05-30 1998-11-10 Lehigh University Methods for the manufacture and use of antimicrobial sterol conjugates
US5874597A (en) 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US6143738A (en) 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5763430A (en) 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5795885A (en) 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
JP4104164B2 (ja) * 1995-06-07 2008-06-18 ジェネーラ コーポレーション ナトリウム／プロトン交換体（ｎｈｅ）の阻害剤として有用なアミノステロール化合物、同阻害剤を使用する薬学的方法および組成物、ならびに化合物のｎｈｅ阻害効果を評価する方法
US5994336A (en) 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
US5840936A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5744453A (en) 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
DE69722793T2 (de) 1996-04-26 2004-05-19 Genaera Corp. Squalamin in kombination mit anderen antikrebs-mittelen zur behandlung von tumoren
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
WO1997044044A1 (en) 1996-05-17 1997-11-27 Magainin Pharmaceuticals Inc. Therapeutic uses for an aminosterol compound
AU5194998A (en) 1996-11-01 1998-05-29 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and uses therefor
US6388108B1 (en) 1998-08-12 2002-05-14 Genaera Corporation Aminosterol compounds and uses thereof
US6288089B1 (en) * 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
WO2002032376A2 (en) 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
US7144877B2 (en) * 2000-10-06 2006-12-05 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
KR101166000B1 (ko) * 2002-01-28 2012-07-16 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US7981876B2 (en) 2005-04-25 2011-07-19 Ohr Pharmaceuticals, Inc. Polymorphic and amorphous salt forms of squalamine dilactate
TW200927755A (en) 2007-09-06 2009-07-01 Genaera Corp A method for treating diabetes
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
WO2011056650A2 (en) 2009-10-27 2011-05-12 Michael Zasloff Methods and compositions for treating and preventing viral infections
WO2011066260A2 (en) 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
KR102057812B1 (ko) 2012-04-20 2019-12-19 오에이치알 파마서티컬, 인코포레이티드 Ptp1b 연관 질병의 치료용 아미노스테로이드
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
EP2934543B1 (en) 2012-12-20 2018-10-31 Mount Desert Island Biological Laboratory Stimulation and enhancement of regeneration of tissues
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Also Published As

Publication number Publication date
CA2951720C (en) 2023-09-26
US10040817B2 (en) 2018-08-07
US20170327530A1 (en) 2017-11-16
ES2878077T3 (es) 2021-11-18
JP6692300B2 (ja) 2020-05-13
US10208080B2 (en) 2019-02-19
BR112016029917A2 (pt) 2017-08-22
US20180319837A1 (en) 2018-11-08
DK3157531T3 (da) 2021-07-05
MX2021005489A (es) 2021-06-18
JP2017519775A (ja) 2017-07-20
US20190185513A1 (en) 2019-06-20
US10208079B2 (en) 2019-02-19
CA2951720A1 (en) 2015-12-30
US20150368290A1 (en) 2015-12-24
US20170326156A1 (en) 2017-11-16
JP2020097587A (ja) 2020-06-25
US10633413B2 (en) 2020-04-28
EP3157531B1 (en) 2021-03-31
RS62064B1 (sr) 2021-07-30
US20180002370A1 (en) 2018-01-04
US20180327445A1 (en) 2018-11-15
US11440936B2 (en) 2022-09-13
CN106535902A (zh) 2017-03-22
LT3157531T (lt) 2021-07-12
CY1124554T1 (el) 2022-07-22
EP3157531A4 (en) 2018-05-16
CN106535902B (zh) 2021-05-25
US10975116B2 (en) 2021-04-13
US10196420B2 (en) 2019-02-05
HUE054828T2 (hu) 2021-10-28
MX2016017368A (es) 2017-08-24
CN113559108A (zh) 2021-10-29
US20190194243A1 (en) 2019-06-27
PT3157531T (pt) 2021-07-01
SI3157531T1 (sl) 2021-09-30
EP3157531A1 (en) 2017-04-26
US20190194244A1 (en) 2019-06-27
JP7010979B2 (ja) 2022-02-10
US20220220148A1 (en) 2022-07-14
WO2015200195A1 (en) 2015-12-30
HRP20211005T1 (hr) 2021-09-17

Similar Documents

Publication Publication Date Title
PL3349783T3 (pl) Kompozycje i sposoby do leczenia chorób
HUE054828T2 (hu) Eljárások és készítmények a bél enteroendokrin rendszerének stimulálására a vele kapcsolatos betegségek és állapotok kezelésére
HK1246179A1 (zh) 治療視網膜疾病的方法
SG10201913564WA (en) Compositions and methods for treatment of neurological disorders
IL246791A0 (en) Compositions and methods for treating eye diseases
IL285003A (en) Treatment of episode disorders
HUE055913T2 (hu) Módszerek és készítmények a glioblastoma diagnosztizálására és kezelésére
IL253118A0 (en) Methods for treating inflammatory diseases
HK1252037A1 (zh) 治療炎性疾病的方法
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
HK1245127A1 (zh) 治療腦疾病的方法和組合物
HK1258994A1 (zh) 用於疾病治療的方法
HK1247818A1 (zh) 治療疾病的方法
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
IL259710A (en) Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases
HK1244782A1 (zh) 用於治療疾病和病癥的組合物和方法
HK1246271A1 (zh) 用於合成羥基-三甘油酯的方法及其用於預防和治療疾病的用途
HK1243937A1 (zh) 治療疾病的方法
IL257689B (en) Pharmaceutical preparations and methods for treating diseases related to lack of oxygen
GB201516303D0 (en) Compositions and methods relating to the treatment of diseases
SG11201705889VA (en) Prevention or Treatment of Uratic or Gouty Diseases
GB201516437D0 (en) Compositions and methods relating to the treatment of disease
AP2016009662A0 (en) Combination of taurine and racemethionine for treatment of liver diseases